These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37681028)

  • 41. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The optimal timing of FDG-PET/CT in non-small cell lung cancer diagnosis and staging in an Australian centre.
    Johnson A; Norman R; Piccolo F; Manners D
    BMC Pulm Med; 2021 Jul; 21(1):209. PubMed ID: 34210303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Receipt of Positron Emission Tomography-Computed Tomography With Non-Small Cell Lung Cancer Mortality in the Veterans Affairs Health Care System.
    Vella M; Meyer CS; Zhang N; Cohen BE; Whooley MA; Wang S; Hope MD
    JAMA Netw Open; 2019 Nov; 2(11):e1915828. PubMed ID: 31747036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
    Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.
    Roengvoraphoj O; Käsmann L; Eze C; Taugner J; Gjika A; Tufman A; Hadi I; Li M; Mille E; Gennen K; Belka C; Manapov F
    Transl Lung Cancer Res; 2020 Jun; 9(3):541-548. PubMed ID: 32676318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
    Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
    Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thoracic staging with
    Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
    Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
    Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
    Ganem J; Thureau S; Gouel P; Dubray B; Salaun M; Texte E; Vera P
    PLoS One; 2019; 14(10):e0222885. PubMed ID: 31603916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by
    Ottestad AL; Johansen H; Halvorsen TO; Dai HY; Wahl SGF; Emdal EF; Grønberg BH
    BMC Cancer; 2023 Jul; 23(1):646. PubMed ID: 37434111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elevated tumor-to-liver uptake ratio (TLR) from
    Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study.
    Kanzaki R; Higashiyama M; Fujiwara A; Tokunaga T; Maeda J; Okami J; Kozuka T; Hosoki T; Hasegawa Y; Takami M; Tomita Y; Kodama K
    Lung Cancer; 2011 Mar; 71(3):333-7. PubMed ID: 20619479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.